Basic HTML Version
66
Choroby Serca i Naczyń 2012, tom 9, nr 2
www.chsin.viamedica.pl
PIŚMIENNICTWO
1. Goldhaber S.Z., Hennekens C.H., Evans D.A., Newton E.C., Godleski J.J.
Factors associated with correct antemortem diagnosis of major pulmonary
embolism.
Am. J. Med.
1982; 73: 822–826.
2. Rubinstein I., Murray D., Hoffstein V. Fatal pulmonary emboli in hospital-
ized patients. An autopsy study.
Arch. Intern. Med.
1988; 148: 1425–1426.
3. Pineda L.A., Hathwar V.S., Grant B.J. Clinical suspicion of fatal pulmonary
embolism.
Chest
2001; 120: 791–795.
4. Nicolaides A.N., Breddin H.K., Fareed J. i wsp. Prevention of venous throm-
boembolism. International Consensus Statement. Guidelines compiled in
accordance with the scientific evidence.
Int. Angiol.
2001; 20: 1–37.
5. Cohen A.T., Agnelli G., Anderson F.A. i wsp. VTE Impact Assessment Group
in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number
of VTE events and associated morbidity and mortality.
Thromb. Haemost.
2007; 98: 756–764.
6. Niżankowski R. Komentarz do „Wytyczne profilaktyki i leczenia żylnej cho-
roby zakrzepowo-zatorowej” (
Med. Prakt.
2002; 5, supl.).
Med. Prakt.
2002;
5: 100–101.
7. Heit J.A., O’Fallon W.M., Petterson T.M. i wsp. Relative impact of risk factors
for deep vein thrombosis and pulmonary embolism: a population-based
study.
Arch. Intern. Med.
2002; 162: 1245–1248.
8. Zawilska K., Jaeschke R., Tomkowski W. i wsp. Polish guidelines for the
prevention and treatment of venous thromboembolism: 2009 update.
Pol.
Arch. Med. Wewn.
2009; 119 (supl. 1): 1–69.
9. Cohen A.T., Tapson V.F., Bergmann J.F. i wsp.; ENDORSE Investigators.
Venous thromboembolism risk and prophylaxis in the acute hospital care
setting (ENDORSE study): a multinational cross-sectional study.
Lancet
2008; 371: 387–394. Errata w:
Lancet
2008; 371: 1914.
10. Musiał J., Sydor W.J.; ENDORSE Investigators-Poland. Venous thromboem-
bolism risk and prophylaxis in the acute hospital care setting — results of
the ENDORSE study in Poland.
Pol. Arch. Med. Wewn.
2008; 118: 555–561.
11. Antithrombic and thrombolytic therapy, 8th edition. ACCP Guidelines.
Chest
2008; 133 (supl.): 67S–968S.
12. Brandjes D.P., Büller H.R., Heijboer H. i wsp. Randomised trial of effect of
compression stockings in patients with symptomatic proximal-vein throm-
bosis.
Lancet
1997; 349: 759–762.
13. Arpaia G., Cimminiello C., Mastrogiacomo O., de Gaudenzi E. Efficacy of
elastic compression stockings used early or after resolution of the edema
on recanalization after deep venous thrombosis: the COM.PRE Trial.
Blood
Coagul. Fibrinolysis
2007; 18: 131–137.
14. CLOTS Trials Collaboration; Dennis M., Sandercock P.A., Reid J. i wsp.
Effectiveness of thigh-length graduated compression stockings to reduce
the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre,
randomised controlled trial.
Lancet
2009; 373: 1958–1965.
15. Prandoni P., Lensing A.W., Cogo A. i wsp. The long-term clinical course of
acute deep venous thrombosis.
Ann. Intern. Med.
1996; 125: 1–7.
16. Prandoni P., Kahn S.R. The long-term clinical course of acute deep venous
thrombosis. Post-thrombotic syndrome: prevalence, prognostication and
need for progress.
Br. J. Haematol.
2009; 145: 286–295.
17. Pengo V., Lensing A.W., Prins M.H. i wsp.; Thromboembolic Pulmonary
Hypertension Study Group. Incidence of chronic thromboembolic pulmo-
nary hypertension after pulmonary embolism.
N. Engl. J. Med.
2004; 350:
2257–2264.
18. House of Commons Health Committee. The prevention of venous throm-
boembolism in hospitalized patients. Second report of Session 2004–05.
Źródło: http://www.parliament.the-stationery-office.co.uk/pa/cm200405/
/cmselect/cmhealth/99/99.pdf
19. Hutten B.A., Prins M.H. Duration of treatment with vitamin K antagonists
in symptomatic venous thromboembolism.
Cochrane Database Syst. Rev.
2006; 25: CD001367.
20. Erkens P.M., Gandara E., Wells P. i wsp. Safety of outpatient treatment in
acute pulmonary embolism.
J. Thromb. Haemost.
2010; 8: 2412–2417.
21. Levine M., Gent M., Hirsh J. i wsp. A comparison of low-molecular-weight
heparin administered primarily at home with unfractionated heparin ad-
ministered in the hospital for proximal deep-vein thrombosis.
N. Engl.
J. Med.
1996; 334: 677–681.
22. Koopman M.M., Prandoni P., Piovella F. i wsp. Treatment of venous thrombo-
sis with intravenous unfractionated heparin administered in the hospital as
compared with subcutaneous low-molecular-weight heparin administered
at home. The Tasman Study Group.
N. Engl. J. Med.
1996; 334: 682–687.
23. The Columbus Investigators. Low-molecular-weight heparin in the treat-
ment of patients with venous thromboembolism.
N. Engl. J. Med.
1997;
337: 657–662.
24. Charbonnier B.A., Fiessinger J.N., Banga J.D., Wenzel E., d’Azemar P.,
Sagnard L. Comparison of a once daily with a twice daily subcutaneous low
molecular weight heparin regimen in the treatment of deep vein thrombosis.
Thromb. Haemost.
1998; 79: 897–901.
25. Albanese C., Bellani M., Longatti S. i wsp. Comparison of local tolerability of
two subcutaneous low molecular weight heparins: CY 216 and enoxaparine.
Curr. Ther. Res.
1992; 51: 469–475.
26. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman
G.H. Thromboembolism in hospitalized neutropenic cancer patients.
J. Clin.
Oncol.
2006; 24: 484–490.
27. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Throm-
boembolism is a leading cause of death in cancer patients receiving outpa-
tient chemotherapy.
J. Thromb. Haemost.
2007; 5: 632–634.
28. Lyman G.H., Khorana A.A., Falanga A. i wsp.; American Society of Clinical
Oncology. American Society of Clinical Oncology guideline: recommenda-
tions for venous thromboembolism prophylaxis and treatment in patients
with cancer.
J. Clin. Oncol.
2007; 25: 5490–5505.
29. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Ly-
man G.H. Thromboembolism in hospitalized neutropenic cancer patients.
J. Clin. Oncol.
2006; 24: 484–490.
30. Chew H.K., Wun T., Harvey D., Zhou H., White R.H. Incidence of venous
thromboembolism and its effect on survival among patients with common
cancers.
Arch. Intern. Med.
2006; 166: 458–464.
31. Lyman G.H., Khorana A.A. Cancer, clots and consensus: new understanding
of an old problem.
J. Clin. Oncol.
2009; 27: 4821–4826.
32. Leizorovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., Gold-
haber S.Z.; PREVENT Medical Thromboprophylaxis Study Group. Ran-
domized, placebo-control led trial of dal teparin for the prevent ion of
venous thromboembol ism in acutely i l l medical patients.
Circulat ion
2004; 110: 874–879.
33. Cohen A.T., Davidson B.L., Gallus A.S. i wsp.; ARTEMIS Investigators.
Efficacy and safety of fondaparinux for the prevention of venous thrombo-
embolism in older acute medical patients: randomised placebo controlled
trial.
Br. Med. J.
2006; 332: 325–329.
34. Alikhan R, Cohen AT, Combe S. i wsp. Prevention of venous thromboem-
bolism in medical patients with enoxaparin: a subgroup analysis of the
MEDENOX study.
Blood Coagul. Fibrinolysis
2003; 14: 341–346.
35. Bern M.M., Lokich J.J., Wallach S.R. i wsp. Very low doses of warfarin can
prevent thrombosis in central venous catheters. A randomized prospective
trial.
Ann. Intern. Med.
1990; 112: 423–428.
36. Monreal M., Alastrue A., Rull M. i wsp. Upper extremity deep venous throm-
bosis in cancer patients with venous access devices — prophylaxis with
a low molecular weight heparin (Fragmin).
Thromb. Haemost.
1996; 75:
251–253.
37. Couban S., Goodyear M., Burnell M. i wsp. Randomized placebo-controlled
study of low-dose warfarin for the prevention of central venous catheter-asso-
ciated thrombosis in patients with cancer.
J. Clin. Oncol.
2005; 23: 4063–4069.
38. Verso M., Agnelli G., Bertoglio S. i wsp. Enoxaparin for the prevention of
venous thromboembolism associated with central vein catheter: a double-
-blind, placebo-controlled, randomized study in cancer patients.
J. Clin.
Oncol.
2005; 23: 4057–4062.
39. Karthaus M., Kretzschmar A., Kröning H. i wsp. Dalteparin for prevention
of catheter-related complications in cancer patients with central venous
catheters: final results of a double-blind, placebo-controlled phase III trial.
Ann. Oncol.
2006; 17: 289–296.